UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axSpA) and Ankylosing Spondylitis (AS)
Shots:
- UCB to present 24wks data from the P-III (BE MOBILE 1) & (BE MOBILE 2) studies evaluating bimekizumab (160mg, Q4W) vs PBO for the treatment of nr-axSpA & AS at EULAR 2022
- The results demonstrated patients achieving ASAS40 (47.7% vs 21.4% & 44.8% vs 22.5%), ASAS-PR at wk16 (25.8% vs 7.1% & 24.0% vs 7.2%), mean change from baseline in BASFI (-2.5 vs -1.0 & -2.2 vs -1.1) & in ASQoL (-5.2 vs -2.5 & -4.9 vs -3.2)
- The company has also announced a new post-hoc analysis from the P-IIb (BE AGILE) study evaluating bimekizumab for the treatment of AS with results showing maintenance of clinical response over 3yrs & data to be presented at EULAR 2022
Ref: PR Newswire | Image: UCB
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
